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OBJECTIVE — To examine the contribution of the CTLA4 gene in the susceptibility to ful-
minant type 1 diabetes and compare it with classic type 1A diabetes.
RESEARCH DESIGN AND METHODS — We genotyped the 49GA and
CT60GAvariantsoftheCTLA4geneinfulminanttype1diabeticpatients(n55),classictype
1A diabetic patients (n  91), and healthy control subjects (n  369). We also assessed serum
levels of the soluble form of CTLA4 (sCTLA4).
RESULTS — The49GGandCT60GGgenotypeswereassociatedwithtype1Adiabetes(P
0.001). In contrast, the CT60AA genotype, but not the 49GA variation, was associated with
fulminanttype1diabetes(P0.05),especiallyinpatientscarryingHLA-DR4(P0.01).Serum
levels of sCTLA4 were signiﬁcantly decreased in patients with fulminant type 1 diabetes (P 
0.05).
CONCLUSIONS — These results suggest that CTLA4 CT60 affects the genetic susceptibility
to fulminant type 1 diabetes. Furthermore, the contribution of CTLA4 to disease susceptibility is
distinct between fulminant type 1 diabetes and classic type 1A diabetes.
Diabetes Care 31:1608–1610, 2008
F
ulminanttype1diabetesisasubtype
of type 1 diabetes characterized by
extremely rapid onset that can be
classiﬁed as type 1B diabetes (1). Al-
though frequent ﬂu-like symptoms prior
to onset suggest the contribution of virus
infection in the etiology of fulminant type
1 diabetes, both environmental and ge-
netic factors are largely unknown. Sus-
ceptibility to classic type 1A diabetes is
determined by multiple genes within the
HLA region and non-HLA genes, includ-
ing INS-VNTR, CTLA4, and PTPN22 (2).
Among them, CTLA4 is associated with
autoimmunity, cancer, allergy, and infec-
tious disease. In the CTLA4 region, a
number of variants, such as 49GA
and CT60, have shown type 1 diabetes
association (3). Although the association
between class II HLA and fulminant type
1 diabetes has been reported (4), the con-
tributionofthenon-HLAgenestothesus-
ceptibility to fulminant type 1 diabetes
has not been investigated. In this study,
we examined the genetic contribution of
the CTLA4 gene to fulminant type 1 dia-
betes compared with classic type 1A
diabetes.
RESEARCH DESIGN AND
METHODS— We examined 55 pa-
tients with fulminant type 1 diabetes
(49% female, median age at onset 35.0
years), 91 patients with classic type 1A
diabetes (57% female, median age at on-
set 17.0 years), and 369 healthy control
subjects. Diagnostic criteria for fulminant
type 1 diabetes are described elsewhere
(1). The criteria for the recruitment of
type1Adiabeticpatientswerepresenceof
diabetic ketosis at onset, duration of hy-
perglycemic symptoms 3 months prior
to initiation of insulin therapy, and posi-
tive for at least one of the anti-islet auto-
antibodies. This study was approved by
the appropriate ethics committees, and
informed consent was obtained from all
subjects.
Genotyping of two single nucleotide
polymorphisms in the CTLA4 gene,
49GA (rs231775) and CT60
(rs3087243), was performed as reported
previously (5). Serum concentration of
sCTLA4 was measured by enzyme-linked
immunosorbent assay using human solu-
ble CTLA4 (sCTLA4) kit (MedSystems
Diagnostics, Vienna, Austria), according
to the manufacturer’s protocol. Sera from
type 1 diabetic patients were obtained at
disease onset and stored at 20°C until
use.
The signiﬁcance of differences in the
distribution of genotypes between case
and control subjects was determined by

2 test or Fisher’s exact probability test.
Comparisons of the sCTLA4 levels were
made by ANOVA with phenotypic group
alone and ANOVA with phenotypic
groupandCTLA4genotype.P0.05was
considered to be statistically signiﬁcant.
RESULTS— The 49GA variant
was associated with classic type 1A dia-
betes but not with fulminant type 1 di-
abetes (Table 1). In contrast, the
contribution of CT60 to disease is dis-
tinct from that of 49GA. The fre-
quency of the CT60AA genotype in
fulminant type 1 diabetic patients was
signiﬁcantly higher than in control sub-
jects (P  0.021) and type 1A diabetic
patients (P  0.031). CT60GG was as-
sociated with type 1A diabetes (P 
0.008). Because of the strong associa-
tion of HLA-DR4 in both patient groups
(1), the effect of CTLA4 on type 1 dia-
betessusceptibilityrelativetoHLA-DR4
was also examined. Among DR4-
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the CT60AA genotype was signiﬁcantly
increased in patients with fulminant
type 1 diabetes (P  0.005). However,
stratiﬁcation of patients by the presence
or absence of HLA-DR4 did not affect
the association between the 49GG ge-
notype and type 1A diabetes (Table 1).
It has been reported that the CT60G
allele might be associated with lower pro-
duction of sCTLA4 mRNA (3). We there-
fore determined serum sCTLA4 levels.
The mean sCTLA4 levels in fulminant
type 1 diabetic patients (0.56  0.24
ng/ml [mean  SD], n  36) was signiﬁ-
cantly lower than those in type 1A dia-
betic patients (0.94  0.87 ng/ml, n 
45)andcontrolsubjects(0.890.76ng/
ml, n  23) (P  0.043). A mixed-model
ANOVA using phenotypic group (fulmi-
nant type 1 diabetes, type 1A diabetes,
andcontrol)andCT60genotype(GGand
GAAA)asfactorialﬁxedeffectsrevealed
no differences in sCTLA4 levels between
CT60 genotypes (P  0.76) or pheno-
type/genotype interactions (P  0.40).
CONCLUSIONS — CTLA4, which
deliversinhibitorysignalstoT-cellactiva-
tion, is expressed on the surface of acti-
vated T-cells and regulatory T-cells, and
the lack of CTLA4 results in uncontrolled
T-cell–mediated lymphoproliferative dis-
ease (6). Furthermore, CTLA4 also has a
signiﬁcant biological role in attenuating
T-cell responses in the context of an in-
ﬂammatory environment, such as infec-
tion with a pathogen (7). We showed that
CTLA4isassociatedwithanincreasedrisk
of fulminant type 1 diabetes and that its
contribution is distinct from classic type
1Adiabetes.Asreportedpreviously(5,8),
a signiﬁcant association between classic
type 1A diabetes and 49GG and
CT60GG genotype was also found in the
present study. However, the CT60AA ge-
notype contributes to the susceptibility to
fulminant type 1 diabetes. Moreover, it is
implicated that HLA-DR4 inﬂuences the
association of fulminant type 1 diabetes
with the CT60AA genotype.
In this study, we also revealed that
serum sCTLA4 level in fulminant type 1
diabetic patients were signiﬁcantly lower
than those in type 1A diabetic patients
and control subjects. Although it remains
unknown how sCTLA4 regulates T-cell
activation, recombinant sCTLA4 inhibits
T-cell proliferation in vitro. Furthermore,
sCTLA4 is constitutively expressed in
nonstimulated T-cells, and its expression
is downregulated after T-cell activation
(9). Therefore, the decreased levels of
sCTLA4 might indicate a lower potential
of T-cell inhibition in fulminant type 1
diabetes, which might be caused by func-
tional defects leading to reduced produc-
tion of sCTLA4 or ongoing activation of
the immune system eventually leading to
decreased levels of sCTLA4.
In conclusion, the present study im-
plicates that CTLA4 confers susceptibility
to fulminant type 1 diabetes. Further-
more, the different contributions of
CTLA4 to susceptibility to fulminant and
classic type 1A diabetes indicate that the
underlying immune process–primed
	-cell injury might be distinct between
these subtypes of type 1 diabetes.
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